Pharvaris price target raised to $65 by Leerink Partners
Leerink Partners raised its Pharvaris price target to $65.00 per share from $50.00 and maintained an Outperform rating, per TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.